Neuberger Berman Group
EPZM

Neuberger Berman Group’s Epizyme, Inc EPZM Stock Holding History

Neuberger Berman Group’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-16,015
Closed -$641K – 1677
2013
Q3 		$641K Buy
+16,015
New +$542K ﹤0.01% 1258

Other funds holding EPZM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group's EPZM Position: Q4 2013 in Review

Neuberger Berman Group sold out of Epizyme, Inc (EPZM) in Q4 2013, closing a stake of 16,015 shares — an estimated $641K sold.

Neuberger Berman Group first reported a position in EPZM in Q3 2013 and held it in 1 quarter. The position peaked at $641K in Q3 2013. 60 funds tracked by Wall St. Rank hold EPZM as of Q4 2013.

  • Neuberger Berman Group reported no remaining Epizyme, Inc position as of Q4 2013 after selling out during the quarter.
  • Neuberger Berman Group sold 16,015 Epizyme, Inc shares in Q4 2013, an estimated $641K.
  • Neuberger Berman Group first reported a position in Epizyme, Inc in Q3 2013 and held it in 1 quarter.
  • Neuberger Berman Group's Epizyme, Inc position peaked at $641K in Q3 2013.
  • 60 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2013.

Based on Neuberger Berman Group's 13F filing for Q4 2013, filed 11 Feb 2014.